Advances in Conducting Retrospective Chart Review Studies: Use of Electronic Report Forms and Database in a Community Study in Anemic Patients With Myelodysplastic Syndrome (MDS)

2.50
Hdl Handle:
http://hdl.handle.net/10755/165362
Category:
Abstract
Type:
Presentation
Title:
Advances in Conducting Retrospective Chart Review Studies: Use of Electronic Report Forms and Database in a Community Study in Anemic Patients With Myelodysplastic Syndrome (MDS)
Author(s):
Sullivan, T.; Patton, J.; Mun, Y.; Wallace, J.
Author Details:
T. Sullivan, Tennessee Oncology, Nashville, Tennessee, USA; J. Patton; Y. Mun; J. Wallace
Abstract:
Retrospective chart review studies provide important insight to oncology nurses into the current and optimal clinical practices of new therapies. Purpose: Conducting chart reviews are typically difficult, due to nonprospectively planned methods/endpoints and arduous labor spent searching for and entering data into spreadsheets. Improvement of this process is a recognized need and welcomed among study nurses. Theoretical/Scientific Framework: In anemic patients with MDS, we implemented new guidelines to substitute darbepoetin alfa 200 mcg Q2W for current epoetin alfa regimens. To evaluate the impact of switching to darbepoetin alfa, we designed a retrospective cohort study and developed an electronic database and data forms to efficiently capture prespecified hematologic endpoints and drug usage data. Methods: Patients who started epoetin alfa between May 2003-January 2004 were categorized into 1 of 2 patient groups: darbepoetin alfa (received prior epoetin alfa, switched to darbepoetin alfa after guideline implementation) and epoetin alfa (received prior epoetin alfa, continued epoetin alfa after guideline implementation). Patient data was extracted for 16 weeks before and after the switch to darbepoetin alfa. The database and electronic forms were created using Microsoft Access. At baseline (the time of the switch) and at all timepoints, data for each patient, including demographics, hemoglobin levels, erythropoietic agent dose and schedule, and transfusions, were entered. Data were analyzed for efficacy and drug utilization. Data Analysis: The electronic data forms were efficient and convenient to use, with data entry for each patient averaging approximately 3 minutes. Reports of patient data were easily accessible and queries were easily resolved. Within 2 weeks of the last patient data entry, data of all prespecified endpoints were analyzed. Hemoglobin response (eg, hemoglobin increase?1-2g/d l) and transfusion rates were either improved for darbepoetin alfa or similar between treatment groups. Findings and Implications: Using electronic data capture, evaluation of our therapeutic substitution guidelines was achieved with minimal errors and substantial convenience to nurses. By participating in retrospective studies, nurses can increase their knowledge of available treatment options for patients and become patient advocates to physicians about the effectiveness of new therapies. Therapeutic substitution with darbepoetin alfa in patients with MDS offers the convenience of less-frequent dosing to patients and caregivers.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2005
Conference Name:
30th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Orlando, Florida, USA
Sponsors:
Funding Sources: This abstract and study were sponsored by Amgen Inc.
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleAdvances in Conducting Retrospective Chart Review Studies: Use of Electronic Report Forms and Database in a Community Study in Anemic Patients With Myelodysplastic Syndrome (MDS)en_GB
dc.contributor.authorSullivan, T.en_US
dc.contributor.authorPatton, J.en_US
dc.contributor.authorMun, Y.en_US
dc.contributor.authorWallace, J.en_US
dc.author.detailsT. Sullivan, Tennessee Oncology, Nashville, Tennessee, USA; J. Patton; Y. Mun; J. Wallaceen_US
dc.identifier.urihttp://hdl.handle.net/10755/165362-
dc.description.abstractRetrospective chart review studies provide important insight to oncology nurses into the current and optimal clinical practices of new therapies. Purpose: Conducting chart reviews are typically difficult, due to nonprospectively planned methods/endpoints and arduous labor spent searching for and entering data into spreadsheets. Improvement of this process is a recognized need and welcomed among study nurses. Theoretical/Scientific Framework: In anemic patients with MDS, we implemented new guidelines to substitute darbepoetin alfa 200 mcg Q2W for current epoetin alfa regimens. To evaluate the impact of switching to darbepoetin alfa, we designed a retrospective cohort study and developed an electronic database and data forms to efficiently capture prespecified hematologic endpoints and drug usage data. Methods: Patients who started epoetin alfa between May 2003-January 2004 were categorized into 1 of 2 patient groups: darbepoetin alfa (received prior epoetin alfa, switched to darbepoetin alfa after guideline implementation) and epoetin alfa (received prior epoetin alfa, continued epoetin alfa after guideline implementation). Patient data was extracted for 16 weeks before and after the switch to darbepoetin alfa. The database and electronic forms were created using Microsoft Access. At baseline (the time of the switch) and at all timepoints, data for each patient, including demographics, hemoglobin levels, erythropoietic agent dose and schedule, and transfusions, were entered. Data were analyzed for efficacy and drug utilization. Data Analysis: The electronic data forms were efficient and convenient to use, with data entry for each patient averaging approximately 3 minutes. Reports of patient data were easily accessible and queries were easily resolved. Within 2 weeks of the last patient data entry, data of all prespecified endpoints were analyzed. Hemoglobin response (eg, hemoglobin increase?1-2g/d l) and transfusion rates were either improved for darbepoetin alfa or similar between treatment groups. Findings and Implications: Using electronic data capture, evaluation of our therapeutic substitution guidelines was achieved with minimal errors and substantial convenience to nurses. By participating in retrospective studies, nurses can increase their knowledge of available treatment options for patients and become patient advocates to physicians about the effectiveness of new therapies. Therapeutic substitution with darbepoetin alfa in patients with MDS offers the convenience of less-frequent dosing to patients and caregivers.en_GB
dc.date.available2011-10-27T12:17:11Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:17:11Z-
dc.conference.date2005en_US
dc.conference.name30th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationOrlando, Florida, USAen_US
dc.description.sponsorshipFunding Sources: This abstract and study were sponsored by Amgen Inc.-
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.